KDR and head and neck squamous cell carcinoma: Vandetanib, a TKI that inhibits both EGFR and VEGFR, resulted in an ORR of 13% (PR in 2/15 patients) when combined with docetaxel in platinum-resistant R/M HNSCC [121].